---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-027742"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2026-01-29T23:59:59+00:00"
generated_at: "2026-05-16T06:31:37.865564+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences raises ~$7.3M via warrant exercise; issues new warrants

## Summary
- Two holders exercised 8,544,999 pre-split Class I warrants at $0.86/share, gross proceeds ~$7.3M.
- Company issued 17,089,998 pre-split new Class J warrants at $0.86/share, exercisable only after stockholder approval.
- Net proceeds to fund clinical development and working capital.
- Third investor withdrew; filing corrects earlier press release that had included them.
- Roth Capital Partners received 8% cash fee of gross proceeds as financial advisor.

## SEC filing metadata
- accession: 0001193125-26-027742
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2026-01-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000119312526027742/0001193125-26-027742-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000119312526027742/revb-20260126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-027742
- JSON: https://secwatch.observer/filing/0001193125-26-027742.json
- Plain text: https://secwatch.observer/filing/0001193125-26-027742.txt

## Key facts
- Equity Issuances
  REVELATION BIOSCIENCES, INC. issued 17,089,998 pre-split (4,272,500 post-split) new common stock warrants of warrant to two holders for aggregate gross proceeds of approximately $7.3 million from the exercise of Existing Warrants.
  - Security: warrant
  - Shares: 17,089,998 pre-split (4,272,500 post-split) new common stock warrants
  - Purchaser: two holders
  - Consideration: aggregate gross proceeds of approximately $7.3 million from the exercise of Existing Warrants
  source text: new common stock warrants (the “Class J Common Stock Warrants”) as described below. The aggregate gross proceeds from the exercise of the Existing Warrants is approximately $7.3 million, before deducting financial advisory fees. The issuance of the Class J Common Stock Warrants was structured as an at-market transaction under Nasdaq rules. The Company intends to
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000119312526027742/0001193125-26-027742-index.htm
- Material Agreements
  REVELATION BIOSCIENCES, INC. entered into Inducement Letters with two holders valued at approximately $7.3 million (effective 2026-01-23).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: two holders
  - Value: approximately $7.3 million
  - Effective: 2026-01-23
  source text: On January 23, 2026, Revelation Biosciences, Inc. (the “Company”) entered into warrant exercise inducement offer letters (the “Inducement Letters”) with two holders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000119312526027742/0001193125-26-027742-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.